The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation

Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6

(2017) Miki Furukawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma

(2017) Bernhard Gillissen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Natural history of t(11;14) multiple myeloma

(2017) A Lakshman et al.   LEUKEMIA

Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells

(2016) Pasupathi Sundaramoorthy et al.   Acta Biomaterialia

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

Novel self-micellizing anticancer lipid nanoparticles induce cell death of colorectal cancer cells

(2015) Pasupathi Sundaramoorthy et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

(2015) S M Matulis et al.   LEUKEMIA

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

(2015) R Bajpai et al.   ONCOGENE

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

(2015) G S Choudhary et al.   Cell Death & Disease

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma

(2014) J. Kummetha Venkata et al.   BLOOD

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome

(2013) Gang An et al.   LEUKEMIA RESEARCH

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro

(2013) J. Hu et al.   MOLECULAR CANCER THERAPEUTICS

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Editorial [Hot Topic: Therapeutic Targeting of the Sphingolipid “Biostat” in Hematologic Malignancies (Guest Editors: Thomas P. Loughran and Hong-Gang Wang)]

(2012) Thomas P. Loughran et al.   Anti-Cancer Agents in Medicinal Chemistry

MYC addiction: a potential therapeutic target in MM

(2012) W. M. Kuehl et al.   BLOOD

Lipid metabolism in cancer

(2012) Claudio R. Santos et al.   FEBS Journal

Sphingolipids in cancer

(2011) Hideki Furuya et al.   CANCER AND METASTASIS REVIEWS

β-Lapachone Significantly Increases the Effect of Ionizing Radiation to Cause Mitochondrial Apoptosis via JNK Activation in Cancer Cells

(2011) Moon-Taek Park et al.   PLoS One

S1P metabolism in cancer and other pathological conditions

(2010) Weng In Leong et al.   BIOCHIMIE

Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation

(2010) Ashley J. Snider et al.   BIOCHIMIE

A study design to investigate the effect of short-form Sun-style Tai Chi in improving functional exercise capacity, physical performance, balance and health related quality of life in people with Chronic Obstructive Pulmonary Disease (COPD)

(2010) R.W.M. Leung et al.   Contemporary Clinical Trials

Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance

(2010) Suriyan Ponnusamy et al.   Future Oncology

Therapeutic applications of bioactive sphingolipids in hematological malignancies

(2010) Huseyin Atakan Ekiz et al.   INTERNATIONAL JOURNAL OF CANCER

Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect

(2010) M. Li et al.   MOLECULAR CANCER THERAPEUTICS

Sphingolipids in inflammation: pathological implications and potential therapeutic targets

(2009) Graeme F. Nixon   BRITISH JOURNAL OF PHARMACOLOGY

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling

(2008) Michael Maceyka et al.   JOURNAL OF LIPID RESEARCH

Caspase-2 Cleavage of BID Is a Critical Apoptotic Signal Downstream of Endoplasmic Reticulum Stress

(2008) J.-P. Upton et al.   MOLECULAR AND CELLULAR BIOLOGY

Sphingolipids: players in the pathology of metabolic disease

(2008) L. Ashley Cowart   TRENDS IN ENDOCRINOLOGY AND METABOLISM